Literature DB >> 10814877

Expression of a TGF-beta1 inducible gene, TSC-36, causes growth inhibition in human lung cancer cell lines.

K Sumitomo1, A Kurisaki, N Yamakawa, K Tsuchida, E Shimizu, S Sone, H Sugino.   

Abstract

TSC-36 (TGF-beta1-stimulated clone 36) is a TGF-beta1 inducible gene whose product is an extracellular glycoprotein that contains a single follistatin module. TSC-36 is highly expressed in the lung, but its physiological function is unknown. In an attempt to elucidate it, we investigated the effect of TSC-36 on proliferation of human lung cancer cell lines. We found a correlation between expression of TSC-36 and cell growth: TSC-36 mRNA was not detected in cells derived from small cell lung cancer (SCLC) cells, a highly aggressive neoplasm, but was detected in some non-small cell lung cancer (NSCLC) cells, a moderately aggressive neoplasm. This suggested an antiproliferative function for TSC-36. To address this question, NSCLC PC-14 cells, which express very low level of TSC-36 protein, were transfected with TSC-36 cDNA and the proliferative capacity of stable transfectants was determined by measuring the doubling time, colony forming activity in soft agar and the level of incorporation of (3)H-thymidine into DNA. Under normal culture conditions, the transfected cells showed a longer doubling time, lower plating efficiency and lower rate of DNA synthesis than the parental cells and the control neo transfectant cells. These findings suggested that expression of TSC-36 caused growth inhibition in human lung cancer cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10814877     DOI: 10.1016/s0304-3835(00)00407-9

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  22 in total

1.  DIP2A functions as a FSTL1 receptor.

Authors:  Noriyuki Ouchi; Yasuhide Asaumi; Koji Ohashi; Akiko Higuchi; Saki Sono-Romanelli; Yuichi Oshima; Kenneth Walsh
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

2.  Structural and functional study of FK domain of Fstl1.

Authors:  Xinxin Li; Lian Li; Yue Chang; Wen Ning; Xinqi Liu
Journal:  Protein Sci       Date:  2019-08-09       Impact factor: 6.725

3.  Follistatin-like 1 (Fstl1) is a bone morphogenetic protein (BMP) 4 signaling antagonist in controlling mouse lung development.

Authors:  Yan Geng; Yingying Dong; Mingyan Yu; Long Zhang; Xiaohua Yan; Jingxia Sun; Long Qiao; Huixia Geng; Masahiro Nakajima; Tatsuya Furuichi; Shiro Ikegawa; Xiang Gao; Ye-Guang Chen; Dianhua Jiang; Wen Ning
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

4.  Follistatin-like 1 regulates renal IL-1β expression in cisplatin nephrotoxicity.

Authors:  Derek C Adams; Michele J Karolak; Barry W Larman; Lucy Liaw; James D Nolin; Leif Oxburgh
Journal:  Am J Physiol Renal Physiol       Date:  2010-09-22

5.  Follistatin-like 1 in chronic systolic heart failure: a marker of left ventricular remodeling.

Authors:  Ali El-Armouche; Noriyuki Ouchi; Komei Tanaka; Gheorghe Doros; Katrin Wittköpper; Thomas Schulze; Thomas Eschenhagen; Kenneth Walsh; Flora Sam
Journal:  Circ Heart Fail       Date:  2011-05-27       Impact factor: 8.790

6.  Activins and follistatins: Emerging roles in liver physiology and cancer.

Authors:  Emanuel Kreidl; Deniz Oztürk; Thomas Metzner; Walter Berger; Michael Grusch
Journal:  World J Hepatol       Date:  2009-10-31

7.  The expression and post-transcriptional regulation of FSTL1 transcripts in placental trophoblasts.

Authors:  Jean-Francois Mouillet; Takuya Mishima; Andrea Mollica do Amarante Paffaro; Tony W Parks; Judy A Ziegler; Tianjiao Chu; Yoel Sadovsky
Journal:  Placenta       Date:  2015-09-10       Impact factor: 3.481

8.  Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart.

Authors:  Yuichi Oshima; Noriyuki Ouchi; Kaori Sato; Yasuhiro Izumiya; David R Pimentel; Kenneth Walsh
Journal:  Circulation       Date:  2008-06-02       Impact factor: 29.690

9.  Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/Connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis.

Authors:  Richard A Dean; Georgina S Butler; Yamina Hamma-Kourbali; Jean Delbé; David R Brigstock; José Courty; Christopher M Overall
Journal:  Mol Cell Biol       Date:  2007-10-01       Impact factor: 4.272

10.  Downregulated expression of the secreted glycoprotein follistatin-like 1 (Fstl1) is a robust hallmark of preadipocyte to adipocyte conversion.

Authors:  Yu Wu; Shengli Zhou; Cynthia M Smas
Journal:  Mech Dev       Date:  2010-01-04       Impact factor: 1.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.